In cancers of the breast and ovary, SYVN1 inhibits tumor progression by promoting the ubiquitination of substrate proteins, such as PFAK [23], CPT2 [24], and SLC7A11 [25], which can lead to either their degradation or stabilization. This evidence concerns the gene SYVN1 and neoplasm.